- Momentum continues to build for Dren Bio after successfully forming highly experienced senior leadership team and earlier this year announcing research collaboration and license deal with Pfizer -
A recent study published in the journal Antiviral Research explored alternative sources of polyclonal antibodies against SARS-CoV-2, which would be more cost-effective, amendable to regulatory approval, and widespread use.
This application note dives into recent research from Boehringer Ingelheim that utilized Twist Bioscience’s silicon-based DNA synthesis platform to produce high-quality, customized oligos for CRISPR screens.
A new study examined the serological immune responses and antibody-dependent cell-mediated phagocytosis in individuals who had either received two doses of a standard vaccine regime, a booster dose following the regime, or a breakthrough infection following vaccination.
In a recent study published in the journal Science, researchers observed differential effector functions of antibodies elicited by Pfizer’s BNT162b2 and Moderna’s messenger ribonucleic acid (mRNA)-1273 coronavirus disease 2019 (COVID-19) vaccines.